Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 172

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Update on the Burden of CKD

Open access
Coresh, Josef · 2017 · Journal of the American Society of Nephrology

Abstract

Recent studies confirm that the global burden of CKD is high but point to interesting trends and methodologic challenges. Data on CKD burden have grown dramatically over the past years, building on the foundation set by standardizing the definition and staging of CKD in 2002. I will briefly summarize recent landmark studies that estimate the global burden of CKD and ESRD better than ever before and key recent papers on CKD prevalence trends. These data will be discussed in the context of the methodologic challenges that we must surpass to attain a good understanding of CKD burden. The global prevalence of CKD was estimated in two meta-analyses.1,2 Their results were remarkably similar, although both note major limitations and methodologic heterogeneity in the studies reviewed. A meta-analysis of 44 country prevalence studies estimated the worldwide prevalence of CKD at 13.4% (95% confidence interval [95% CI], 11.7% to 15.1%).2 A meta-analysis of 33 prevalence studies estimated worldwide prevalence of CKD by sex at 10.4% in men (95% CI, 9.3% to 11.9%) and 11.8% in women (95% CI, 11.2% to 12.6%).1 Interestingly, prevalence estimates were approximately 15% higher in low- and middle-income countries compared with high-income countries. Prevalence data in low- and middle-income countries were expanded by a study of convenience samples from 12 countries in six world regions.3 They found a prevalence of 14.3% (95% CI, 14.0% to 14.5%) in general populations and 36.1% (95% CI, 34.7% to 37.6%) in high-risk populations. This study also confirmed that awareness of CKD remains very low (6% in the general populations and 10% in high-risk populations). Studies of CKD prevalence in the United States and Europe recently provided some interesting insights. In the United States, several decades of rising CKD prevalence4,5 seem to have reached a plateau in the mid-2000s.6 Interestingly, this reflected a mixed picture—decrease in CKD prevalence at older age in the face of a continued rise in high-risk groups, including blacks and patients with diabetes. Among United States patients with diabetes, trends are mixed as well.7 Albuminuria prevalence is decreasing, particularly among white patients with diabetes. This may be due to the higher rates of treatment with angiotensin-converting enzyme inhibitors, statins, and hypoglycemic medications. However, the prevalence of low eGFR among United States patients with diabetes continued to rise from 1988 to 2014. This may be the result of younger age of onset, improved cardiovascular survival, or other factors. Given the rising prevalence of diabetes and obesity, these results indicate that the net effect of improved treatment versus higher prevalence is uncertain, and the recent report of stabilizing overall prevalence should be taken with caution. Conclusions about trends must be tempered by realizing that, unfortunately, even a 0.04 mg/dl higher mean serum creatinine due to calibration issues can contribute to meaningful changes (5% lower eGFR, 23% higher stage G3 CKD, and 12% higher overall CKD prevalence estimate for the United States).4 European studies of CKD burden were recently reviewed, and their results were aggregated.8,9 Overall, the results support a high prevalence of CKD similar to that of the United States. However, the studies also showed marked variation in prevalence across countries from 3.3% in Norway to 17.3% in northwest Germany. Much of the variation persisted, despite stratification by diabetes and hypertension and attempts to standardize definitions and assays. It is unclear how much of the variation is explained and how much is due to residual methodologic variation. The same group nicely summarized the limitations of the existing literature reporting prevalence of CKD in the European adult general population. The majority of studies did not report the sampling frame used, and response rates varied from 10% to 87%. Additional variation was seen in the creatinine assay (67% Jaffe and 13% enzymatic, with 29% calibrated to isotope dilution mass spectrometry), the equation used to estimate GFR (52% Chronic Kidney Disease Epidemiology Collaboration and 75% Modification of Diet in Renal Disease), definition of CKD (92% used eGFR<60), inclusion of urinary markers (in 60% of studies), and reporting of 95% CIs (39% of studies). The 2013 Kidney Disease Improving Global Outcomes guidelines keep the same definition of CKD, but few of the studies to date incorporate the updated staging, which includes cause, GFR category, and albuminuria category as parallel measures. In summary, the literature is improving, but inferences on the basis of published data are still quite limited. Our understanding of RRT globally, both provided and needed, was advanced by a recent Lancet publication.10 Overall, this work estimates that, in 2010, 2.6 million people received RRT worldwide, whereas the number of patients needing RRT is between 4.9 and 9.7 million. It confirmed the very strong

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2016121374

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 172

Metadata

Authors
Coresh, J.
Venue
Journal of the American Society of Nephrology
Published
2017-03-16
Volume
28
Issue
4
Pages
1020-1022
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2597200336
Cited by
172
References
5
FWCI
9.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on the Burden of CKD. https://app.cochat.ai/papers/10.1681/asn.2016121374
The paper
Coresh, J. (2017). Update on the Burden of CKD. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2016121374

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.